Recital 136, Commission Decision of 12/12/2023 declaring a concentration to be compatible with the co…

In forcesince 12 Dec 2023

The Parties overlap in the distribution of dairy enzymes (in particular lactase,

catalase and lipase)199, but the only horizontally affected markets are:200 (i) distribution of dairy enzymes in Denmark;

201 (ii) distribution of lactase in Denmark;

202 (iii) distribution of GM produced lactase at global level; (iv) distribution of GM produced lactase in Spain, 203 and; (v) distribution of non-GM produced lactase in Denmark.

195 eRFI to competitors and distributors, question E.1. 196 eRFI to competitors and distributors, question E.3. 197 eRFI to competitors and distributors, question E.4. 198 Form CO. annex 7.G.a 199 Form CO. figure 15. 200 Other overlaps on plausible distribution markets fall under point 5 of the Commission Notice on a simplified treatment of certain concentrations under Council Regulation (EC) No 139/2004 (OJ C 160, 5.5.2023) because of low combined market shares and/or limited increments. That is notably the case for the markets for the distribution of F&B lactase in the EEA and the distribution of GM produced lactase in the EEA in which the Parties have a combined market share above 30% but below 50% and an HHI delta below 150. 201 Combined market share of [40-50]% (Chr. Hansen [30-40]%, Novozymes [10-20]%). A lot of the overlap is caused by Chr. Hansen’s activity in coagulants, that Novozymes is not active in. (Response to RFI 4) 202 Combined market share in all lactases (F&B and DS/OTC) of [20-30]% (Chr. Hansen [5-10]% and Novozymes [10-20]%) and in F&B lactase of [20-30]% (Chr. Hansen [5-10]% and Novozymes [20- 30]%). (Response to RFI 4) 203 Combined market share of [50-60]% (Chr. Hansen [50-60]%, Novozymes [0-5]%). (Response to RFI 4) 204 Combined market share of [30-40]% (Chr. Hansen [10-20]%, Novozymes [20-30]%). (Response to RFI 4) Table 2: Market shares for the distribution of lactase Distribution of lactase – 2022 (value) EEA Global F&B lactase205 GM produced lactase F&B lactase206 GM produced lactase Novozymes (DK) [0-5]% [0-5]% [0-5]% [5-10]% Chr. Hansen (DK) [25-35]% [40-50]% [10-20]% [20-30]% Combined [30-40]% [40-50]% [10-20]% [20-30]% DSM (NL) [40-50]% [30-40]% [10-20]% [10-20]% IFF (US) [5-10]% - [5-10]% [0-5]% Amano (JP) [0-5]% - [0-5]% - Godo (JP) [0-5]% - [0-5]% - Nagase (JP) [0-5]% - [0-5]% - Others [10-20]% [20-30]% [50-60]% [50-60]% Total market size (mEUR) ( 207) […] […] […] […] Source: Form CO. tables 131, 132, 139, 140.

5.2.2.1. The Parties’ views